GMP News and Research

RSS

TPI revenue increases 48.9% to $95.2 million for fiscal year 2011

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the Fiscal Year 2011.

27 Sep 2011

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

NanoBio Corporation announced today that data from recent animal studies of its NanoStat-based intranasal respiratory syncytial virus (RSV) vaccine have been published in PLoS One, an international peer-reviewed online publication.

25 Aug 2011

NIH approves BioTime's four GMP human embryonic stem cell lines

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that four human embryonic stem (hES) cell lines: ESI-035, ESI-049, ESI-051 and ESI-053, developed by a BioTime subsidiary have been approved by the National Institutes of Health (NIH) for inclusion in the NIH Human Embryonic Stem Cell Registry.

20 Aug 2011

Sinovac second quarter sales increase 52.5% to $15.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2011.

12 Aug 2011

NCI, Genesis Biopharma sign CRADA agreement to develop cancer immunotherapies

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, today announced it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.

10 Aug 2011

PharmOut creates online database of Good Manufacturing Practice guidelines

For manufacturers who must comply with current Good Manufacturing Practice (GMP), keeping track of the latest guidelines can be time consuming and difficult. This task is considerably more complex if the manufacturer exports to multiple countries, each with their own GMP requirements.

5 Aug 2011

SynCo Bio commences release of drug products after expansion of Class A zone

SynCo Bio Partners B.V., one of the leading GMP contract manufacturers of biopharmaceuticals today announced that its aseptic filling facility is again fully operational and SynCo has produced and released the first drug product batches for its clients after the expansion of its Class A zone.

4 Aug 2011

NIH, NanoBio sign licensing agreement to develop vaccine against RSV infections

NanoBio Corporation today announced a licensing agreement with the National Institutes of Health (NIH) that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.

4 Aug 2011

Anthera reports increase in second quarter total operating expenses to $22.7 million

Anthera Pharmaceuticals, Inc., today announced financial results and business highlights for the quarter ended June 30, 2011.

29 Jul 2011

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.

22 Jul 2011

Two instruments of Thermo Fisher Scientific win 2011 R&D 100 Award

Thermo Fisher Scientific, the world leader in serving science, today announced that two of its instruments are 2011 R&D 100 Award winners: the Thermo Scientific Evolution 200 series UV-Vis spectrophotometer and the Thermo Scientific Dionex ICS-5000 capillary ion chromatography system.

From Thermo Fisher Scientific Inc. 20 Jul 2011

Seattle Children's inaugurates new center for cancer research

Today, Seattle Children's Research Institute announced the opening of the Center for Childhood Cancer Research.

15 Jul 2011

USANA receives FDA registration to manufacture OTC drugs

USANA Health Sciences, Inc. today announced it has obtained the U.S. Food and Drug Administration's "Drug Establishment Registration," allowing the company to manufacture over-the-counter (OTC) drugs and holding it to a standard well above what is required of a dietary supplement manufacturer.

11 Jul 2011

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Scil Proteins, a private biopharmaceutical company specialized in the research, development and production of recombinant proteins, today announced that it has signed an agreement with Anabasis Pharma.

30 Jun 2011

IOTA NanoSolutions secures funding for commercialisation of ContraSol technology

IOTA NanoSolutions Limited, a specialist formulation company, is pleased to announce today that it has completed a financing round to support the commercialisation of its proprietary nanodispersion formation technology, ContraSol™. New investor, QIB(UK) Plc joins Unilever Ventures Limited (UV) in this financing round.

28 Jun 2011

CSL Biotherapies statement on FDA warning letter

Today the US Food and Drug Administration (FDA) published a Warning Letter issued by its Office of Compliance and Biologics Quality to CSL Biotherapies, a division of CSL Limited. The FDA regulates the manufacture, marketing and distribution of CSL Biotherapies’ influenza vaccine, Afluria®, in the US market.

21 Jun 2011

BioLife becomes the leading supplier of pre-formulated cord blood stem cell freeze media products

BioLife Solutions, Inc., a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced that it has become the leading supplier of pre-formulated GMP cryopreservation media for umbilical cord blood stem cells, a key segment of the Company's strategic biobanking market.

21 Jun 2011

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.

17 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

Bionovo's Menerba Phase 2 trial data to be presented at Annual World Congress on Menopause

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced it will be presenting data from the Phase 2 clinical trial of their lead drug candidate for postmenopausal symptoms, Menerba, to the international community at the 13th Annual World Congress on Menopause in Rome, Italy on June 11, 2011.

4 Jun 2011